Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* The Food and Drug Administration has revised the labeling for saxagliptin (Onglyza) and alogliptin (Nesina), two dipeptidyl peptidase-4 inhibitors used in the treatment of type 2 diabetes, to include a warning that the drugs may increase the risk of heart failure.

 

* Nurses should assess for signs and symptoms of heart failure in patients receiving these drugs and inform patients about this potential adverse effect.